Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Cai

Showing results (251-260 of 270) with videos related to

Pageof 27
Sort By:
Blood Advances|December 6, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failureKuo-Kai Chin, Brian J Ball, Yasmin Abaza, et al.
Hemasphere|July 14, 2025
PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, et al.
Blood Cancer Journal|June 16, 2026
Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitorsNeerav Shukla, Karmelina Charalambous, Shanita Li, et al.
Blood Advances|March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
American Journal of Hematology|March 2, 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapyBrian J Ball, Meier Hsu, Sean M Devlin, et al.
Cancer Discovery|May 31, 2024
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant CellsMichael R Waarts, Shoron Mowla, Meaghan Boileau, et al.
Cancer Discovery|October 12, 2022
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired ResistanceJunhua Lyu, Yuxuan Liu, Lihu Gong, et al.
Blood|September 2, 2020
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemiaWenbin Xiao, Alexander Chan, Michael R Waarts, et al.
Cancer Discovery|July 2, 2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 InhibitionSheng F Cai, S Haihua Chu, Aaron D Goldberg, et al.
Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Pageof 27

Showing results (251-260 of 270) with videos related to

Sort By:
Pageof 27
Blood Advances|December 6, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failureKuo-Kai Chin, Brian J Ball, Yasmin Abaza, et al.
Hemasphere|July 14, 2025
PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, et al.
Blood Cancer Journal|June 16, 2026
Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitorsNeerav Shukla, Karmelina Charalambous, Shanita Li, et al.
Blood Advances|March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
American Journal of Hematology|March 2, 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapyBrian J Ball, Meier Hsu, Sean M Devlin, et al.
Cancer Discovery|May 31, 2024
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant CellsMichael R Waarts, Shoron Mowla, Meaghan Boileau, et al.
Cancer Discovery|October 12, 2022
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired ResistanceJunhua Lyu, Yuxuan Liu, Lihu Gong, et al.
Blood|September 2, 2020
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemiaWenbin Xiao, Alexander Chan, Michael R Waarts, et al.
Cancer Discovery|July 2, 2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 InhibitionSheng F Cai, S Haihua Chu, Aaron D Goldberg, et al.
Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Pageof 27